04234nam 22006375 450 991043761390332120200702024358.01-4614-6543-510.1007/978-1-4614-6543-0(CKB)2550000001041782(EBL)1205331(SSID)ssj0000879291(PQKBManifestationID)11442831(PQKBTitleCode)TC0000879291(PQKBWorkID)10851667(PQKB)11718003(DE-He213)978-1-4614-6543-0(MiAaPQ)EBC1205331(PPN)168305194(EXLCZ)99255000000104178220130228d2013 u| 0engur|n|---|||||txtccrMHC Class I Antigens In Malignant Cells Immune Escape And Response To Immunotherapy /by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera1st ed. 2013.New York, NY :Springer New York :Imprint: Springer,2013.1 online resource (51 p.)SpringerBriefs in Cancer Research,2194-1173 ;1Description based upon print version of record.1-4614-6542-7 Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion.Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.  .SpringerBriefs in Cancer Research,2194-1173 ;1Cancer researchImmunologyMolecular biologyCancer Researchhttps://scigraph.springernature.com/ontologies/product-market-codes/B11001Immunologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B14000Molecular Medicinehttps://scigraph.springernature.com/ontologies/product-market-codes/B1700XCancer research.Immunology.Molecular biology.Cancer Research.Immunology.Molecular Medicine.616.99/4079Aptsiauri Nataliaauthttp://id.loc.gov/vocabulary/relators/aut1059918Garcia-Lora Angel Miguelauthttp://id.loc.gov/vocabulary/relators/autCabrera Teresaauthttp://id.loc.gov/vocabulary/relators/autBOOK9910437613903321MHC Class I Antigens In Malignant Cells2509571UNINA